CytoDyn Inc. Form 8-K (Sept. 20, 2021)
Summary
Form 8-K current report of CytoDyn Inc. dated September 20, 2021. Under Item 8.01 it reports a press release announcing the resolution of the company's lawsuit in the U.S. District Court for the District of Delaware against the activist group led by Paul Rosenbaum and Bruce Patterson. The report does not state the terms; they are in the press release, furnished as Exhibit 99.1. The report is signed by Antonio Migliarese, Chief Financial Officer.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“CytoDyn Inc. Form 8-K (Sept. 20, 2021).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cydy-8-k-filed2021-09-20-0001193125-21-277268-e3e9ca0ace/
, SHA-256 c0e9253c996a2dcddc08392593c22501593096350840b507452ce0b63dbac3f4.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act Date of Report (Date of earliest event reported): September 20, 2021 CytoDyn Inc. (Exact name of registrant as specified in its charter) Delaware | 000-49908 | 83-1887078 (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) 1111 Main Street , Suite 660 Vancouver , Washington 98660 (Address of principal executive offices, including zip code) (360) 980-8524 (Registrant’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☒ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class | Trading Symbol(s) | Name of each exchange on which registered None | None | None Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01. Other Events. On September 20, 2021, CytoDyn Inc. (the “Company”) issued a press release announcing the resolution of its lawsuit brought in the United States District Court for the District of Delaware against the activist group led by Paul Rosenbaum and Bruce Patterson. A copy of the press release is included as Exhibit 99.1 to this Report and is incorporated herein by reference. Item 9.01 | Financial Statements and Exhibits (d) Exhibits 99.1 | Press Release, dated September 20, 2021 104 | Cover Page Interactive Data File (formatted as inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 20, 2021 | CYTODYN INC. By: | /s/ Antonio Migliarese Antonio Migliarese Chief Financial Officer
File and source
- File
- SEC_CYDY_8-K_filed2021-09-20_0001193125-21-277268.htm
- Size
- 22,473 bytes
- SHA-256
- c0e9253c996a2dcddc08392593c22501593096350840b507452ce0b63dbac3f4
- Original
- www.sec.gov